Mouse Model News and Research

RSS

Study: Stem cells play an unexpected role in male pattern balding

Given the amount of angst over male pattern balding, surprisingly little is known about its cause at the cellular level. In a new study, published in the Journal of Clinical Investigation, a team led by George Cotsarelis, MD, chair of the Department of Dermatology at the University of Pennsylvania School of Medicine, has found that stem cells play an unexpected role in explaining what happens in bald scalp.

5 Jan 2011

FDA clears ACT's IND to treat AMD using hESC derived RPE cells

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that the US Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to treat Dry Age-Related Macular Degeneration (AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).

3 Jan 2011

Biglycan protein offers potential therapy for muscular dystrophy

A novel potential therapy based on a natural human protein significantly slows muscle damage and improves function in mice who have the same genetic mutation as boys with the most common form of muscular dystrophy, according to a paper published online Dec. 27 in the Proceedings of the National Academy of Sciences.

28 Dec 2010

Growth hormone may be hazardous for middle aged and older people

A compound which acts in the opposite way as growth hormone can reverse some of the signs of aging, a research team that includes a Saint Louis University physician has shown. The finding may be counter-intuitive to some older adults who take growth hormone, thinking it will help revitalize them.

24 Dec 2010

Researchers study relationship between MITF, ATF2 in melanoma development

Melanoma is one of the least common types of skin cancer, but it is also the most deadly. Melanocytes (pigment-producing skin cells) lose the genetic regulatory mechanisms that normally limit their number, allowing them to divide and proliferate out of control. One such regulator, called MITF, controls an array of genes that influence melanocyte development, function and survival.

24 Dec 2010

Research: Arsenic trioxide may benefit individuals with connective brain tumors

Arsenic is usually thought of as a poison. Despite this, it has been used in medicine for over 2000 years, and the arsenic compound arsenic trioxide (ATO) is FDA approved for the treatment of acute promyelocytic leukemia.

23 Dec 2010

Spirulina dietary supplement may provide clinical benefits for ALS patients

Nutritional supplementation with Spirulina, a nutrient-rich, blue-green algae, appeared to provide neuroprotective support for dying motor neurons in a mouse model of amyotrophic lateral sclerosis, also known as Lou Gehrig's disease, University of South Florida neuroscientists have found.

21 Dec 2010

Study reveals novel role of adenosine signaling in sickle cell disease

Metabolon, Inc., the leader in metabolomics, biomarker discovery and analysis, announces the publication of "Novel Role of Adenosine Signaling in Sickle Cell Disease", in Nature Medicine. Application of non-targeted biochemical profiling (metabolomics) to a mouse model of sickle cell disease (SCD) revealed a detrimental role of adenosine signaling in SCD and suggested novel therapeutic targets. The study was carried out in collaboration with The University of Texas Health Science Center at Houston.

21 Dec 2010

Researchers begin placebo-controlled trial to test drug treatment for Rett syndrome

Researchers at Children's Hospital Boston have begun a randomized, placebo-controlled trial to test a potential drug treatment for Rett syndrome, the leading known genetic cause of autism in girls.

16 Dec 2010

Study reveals immune cell provides new therapeutic strategy for SLE

A new study provides fascinating insight into the underlying pathology associated with the autoimmune disease, systemic lupus erythematosus.

16 Dec 2010

MDA commits to invest funds in FSMA Quinazoline Program

The MDA has committed to invest funds in the FSMA Quinazoline Program at Repligen Corporation to assist in advancing the program to an IND filing with the FDA.

16 Dec 2010

Anoles key to medically applicable regeneration?

Anolis lizards first entered Arizona State University biologist Kenro Kusumi's life in 1980 when, as a member of a junior curator program, he recorded in his field notebook that he had found an Anolis egg on a field trip. Kusumi still has those notes, along with other memorabilia that document the influence that both his early life and more recent experiences have had on his current pursuits in developmental biology.

15 Dec 2010

Osteoporosis drug reduces bone loss in oral cancer

A drug currently approved for osteoporosis treatment has been shown to reduce bone loss in a study of mice with oral cancer, suggesting it could serve as an important supplemental therapy in patients with head and neck cancers that erode bone.

14 Dec 2010

New osteoporosis drug appears to reduce bone loss in mice with oral cancer

14 Dec 2010

UAB researchers pinpoint protein that causes nephrotic syndrome

University of Alabama at Birmingham researchers have pinpointed a protein that compromises the kidney's filtering ability, causing nephrotic syndrome, and demonstrated that a naturally occurring precursor of an acid in the body offers potential for treating some forms of the condition.

13 Dec 2010

Clinical, preclinical results of ISF35 in CLL patients presented at ASH 2010

Memgen, LLC announced the presentation of clinical and preclinical results for its lead product, ISF35, during the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida. The research and clinical development of ISF35 announced today was led by Januario Castro, MD, and Thomas Kipps, MD, PhD, both at the University of California, San Diego.

10 Dec 2010

Medulloblastoma subtypes are separate diseases with different origins

International effort led by St. Jude Children's Research Hospital scientists is expected to fuel development of targeted therapies and aid the search for unique combinations of cells and mutations that lead to other cancers.

8 Dec 2010

Immunomedics reports CD22 antibody produced significant anti-tumor response

Immunomedics, a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that epratuzumab, the Company's humanized anti-CD22 antibody, conjugated with SN-38, the active component of irinotecan, produced significant anti-tumor responses in a mouse model of human lymphoma.

8 Dec 2010

Interference with biofilm detachment mechanisms may prevent biofilm-associated infections

Patients in hospitals and healthcare facilities can develop infections as a result of contamination of indwelling medical devices such as catheters with bacteria that are normal inhabitants of the skin of the patient or health care personnel. The bacterium Staphylococcus epidermidis is a major cause of such infections.

7 Dec 2010

Protein alpha-2-beta-1 integrin suppresses metastasis

Mary Zutter and colleagues, at Vanderbilt University Medical Center, Nashville, have generated data that lead them to suggest that decreased expression of the protein alpha-2 integrin is predictive of tumor dissemination to distant sites and decreased survival in individuals with either breast or prostate cancer.

7 Dec 2010